Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV:
LFST) (FRANKFURT: M5B) (OTCMKTS: NXTTF), a health-tech
company that leverages advancements in science and technology to
build breakthrough companies that transform human wellness, is
pleased to announce that its U.S. biosciences subsidiary Mikra
Cellular Sciences Inc. (“Mikra”) has received its first purchase
order from GNC Holdings, LLC (“GNC”) for Mikra’s CELLF™ v1.2. GNC
is a leading global health and wellness brand that provides
high-quality, science-based products and solutions to consumers.
“Launching our newly formulated cellular health
nutraceutical gel CELLF™ v1.2 with GNC, the global premier health
and wellness brand, is a significant milestone for Mikra and
Lifeist,” said Faraaz Jamal, CEO of Mikra. “We have been working
closely with the team at GNC to make the U.S. roll out of CELLF™
v1.2 a success. They have been extremely helpful fine tuning our
marketing strategies, packaging, and display designs, to create the
greatest impact within their online and retail GNC stores. We look
forward to expanding this strategic relationship beyond CELLF™ v1.2
to include additional product lines as they become available.”
“Congrats to Faraaz and his team who have been
working tirelessly to make the GNC distribution of CELLF™ v1.2 a
reality,” said Meni Morim, CEO of Lifeist. “For the launch we will
take a phased approach, targeting a specific number of GNC stores
before expanding to more stores to ensure that we’re scaling
effectively and meeting consumer needs. I would like to also
announce that as Mikra enters this new stage of growth, Faraaz
Jamal, is transitioning from his role as COO of Lifeist to focus
solely on Mikra to enable growth and lead Mikra into the
future.”
On January 12, 2023 the Company announced a
distribution agreement with GNC to make it the exclusive
distribution partner for CELLF™ v1.2 and its future derivatives in
the United States through retail stores, at gnc.com and
on GNC’s channel on Amazon.com. GNC is a leading global health and
wellness brand that provides high-quality, science-based products
and solutions consumers need to live mighty, live fit, and live
well. With over 4,000 retail locations across the United States and
over 2,000 internationally, GNC is the largest global specialty
retailer of nutritional products.
CELLF™ v1.2 is a cellular health nutraceutical
gel, engineered with a natural biological delivery system to pass
through gastric environments unchanged and deliver directly to
cells. It is formulated with bioactive compounds clinically studied
in more than 145 human studies to positively impact brain, heart,
skin and muscular systems.
CELLF™ v1.2 is currently available on Mikra’s
proprietary e-commerce platform wearemikra.com and Amazon.com,
CELLF™ v1.2 will also be available on GNC.com, GNC’s Amazon store
and in select stores nationwide beginning June 2023.
Mikra is pushing biosciences beyond the expected
with the belief it’s possible to add more valuable, enjoyable years
to your life through rebuilding and protecting your cellular
health.
Rebuild and protect your overall health with
Mikra.
About GNC
GNC is a leading global health and wellness
brand that provides high-quality, science-based products and
solutions consumers need to live mighty, live fit, and Live Well.
The brand touches consumers worldwide by providing its products and
services through company-owned retail locations, domestic and
international franchise locations, digital commerce and strong
wholesale and retail partnerships across the globe. GNC's
diversified, multi-channel business model has worldwide reach and a
well-recognized, trusted brand. By combining exceptional
innovation, product development capabilities and an extensive
global distribution network, GNC manages a best-in-class product
portfolio. www.gnc.com.
About Lifeist Wellness Inc.
Sitting at the forefront of the post-pandemic
wellness revolution, Lifeist leverages advancements in science and
technology to build breakthrough companies that transform human
wellness. Portfolio business units include: CannMart, which
operates a B2B wholesale distribution business facilitating
recreational cannabis sales to Canadian provincial government
control boards including for CannMart Labs, a BHO extraction
facility producing high margin cannabis 2.0 products; Australian
Vapes, one of Australia’s largest online retailers of vaporizers
and accessories; and Mikra, a biosciences and consumer wellness
company developing and selling innovative therapies for cellular
health.
Information on Lifeist and its businesses can be
accessed through the links below:
lifeist.comcannmart.comroilty.coaustralianvaporizers.com.auwearemikra.com
Contacts
Meni Morim, CEOLifeist Wellness Inc.Ph: 647-362-0390Email:
ir@lifeist.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release or has in any way approved
or disapproved of the contents of this press release.
Forward Looking Information
This news release contains “forward-looking
information” within the meaning of applicable securities laws. All
statements contained herein that are not historical in nature
contain forward-looking information. Forward-looking information
can be identified by words or phrases such as “may”, “expect”,
“likely”, “should”, “would”, “plan”, “anticipate”, “intend”,
“potential”, “proposed”, “estimate”, “believe” or the negative of
these terms, or other similar words, expressions and grammatical
variations thereof, or statements that certain events or conditions
“may” or “will” happen.
The forward-looking information contained
herein, including, without limitation, statements related to the
expected availability for purchase by consumers of CELLF™ v1.2 on
GNC.com, GNC’s Amazon store and in select GNC stores nationwide
beginning June 2023, anticipated future distribution in additional
GNC stores and the expected expansion of the strategic relationship
with GNC beyond CELLF™ v1.2 to include additional product lines,
are made as of the date of this news release and is based on
assumptions management believed to be reasonable at the time such
statements were made, including, without limitation, expectations
that CELLF™ v1.2 will be available for purchase through GNC as
anticipated and in a timely manner and gain market acceptance,
Mikra will be able to develop new product lines as anticipated,
sales level of CELLF™ v1.2 will be as anticipated and economically
viable for Mikra and the Company, its expectation that the market
for nutraceutical products in general will remain strong and will
continue to grow as currently anticipated, the market for
nutraceutical products will continue to be a multi-billion dollar
market, the introduction of new products, brands and distribution
channels will generate additional awareness of Mikra’s existing and
future products and increase revenue. While we consider these
assumptions to be reasonable based on information currently
available to management, there is no assurance that such
expectations will prove to be correct. By its nature,
forward-looking information is subject to inherent risks and
uncertainties that may be general or specific and which give rise
to the possibility that expectations, forecasts, predictions,
projections or conclusions will not prove to be accurate, that
assumptions may not be correct and that objectives, strategic goals
and priorities will not be achieved. A variety of factors,
including known and unknown risks, many of which are beyond our
control, could cause actual results to differ materially from the
forward-looking information in this press release. Such factors
include, without limitation: unforeseen developments that would
delay Mikra’s ability to begin sales of CELLF™ v1.2 via GNC as
anticipated, sales of CELLF™ v1.2 failing to achieve the sales
level and other benefits expected from being available for purchase
at GNC stores and online, the exclusive distribution relationship
between the Company and GNC failing to demonstrate and achieve its
anticipated benefits, the Company’s inability to continue to
develop Mikra’s business as a whole, including its inability to
develop new products or increase distribution through retail and
online channels, unanticipated changes to current regulations that
would adversely impact Mikra’s business, the risk that the expected
demand for nutraceutical products in general and those of Mikra in
particular, including CELLF™ v1.2, does not develop as anticipated
and risks relating to the Company’s ability to execute its business
strategy and the benefits realizable therefrom. Additional risk
factors can also be found in the Company’s current MD&A which
has been filed under the Company’s SEDAR profile at www.sedar.com.
Readers are cautioned not to put undue reliance on forward-looking
information. The Company undertakes no obligation to update or
revise any forward-looking information, whether as a result of new
information, future events or otherwise, except as required by
applicable law. Forward-looking statements contained in this news
release are expressly qualified by this cautionary statement.
Source: Lifeist Wellness Inc.
Lifeist Wellness (TSXV:LFST)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Lifeist Wellness (TSXV:LFST)
Gráfica de Acción Histórica
De May 2023 a May 2024